Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06305351 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes
A Phase 1 study, sponsored by Kallyope.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT06305351: Completed Phase 1 study, sponsored by Kallyope.
NCT06305351 is a Phase 1 study that has completed, run by Kallyope. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06305351, a Phase 1 study, has completed, sponsored by Kallyope.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This is a multiple dose study to evaluate the safety, tolerability, PK, and PD of K-757 and K-833 when co-administered in overweight/obese patients with Type 2 diabetes mellitus (T2DM)
Interventions
- DRUG K-757 and K-833 QD
- DRUG K-757 and K-833 BID
- DRUG Matching placebo to K-757 and K-833 QD
- DRUG Matching placebo to K-757 and K-833 BID
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2023-12-07 |
| Est. Completion | 2024-06-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06305351
The ClinicalTrials.gov registry entry for NCT06305351 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kallyope, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which K-757 and K-833 QD is the first listed.
NCT06305351 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06305351 about?
NCT06305351 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes". This is a multiple dose study to evaluate the safety, tolerability, PK, and PD of K-757 and K-833 when co-administered in overweight/obese patients with Type 2 diabetes mellitus (T2DM)
What is the current status of trial NCT06305351?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2023-12-07. Estimated completion is 2024-06-21.
What interventions are being tested in trial NCT06305351?
The interventions under investigation include: K-757 and K-833 QD (DRUG), K-757 and K-833 BID (DRUG), Matching placebo to K-757 and K-833 QD (DRUG), Matching placebo to K-757 and K-833 BID (DRUG).
Who is sponsoring clinical trial NCT06305351?
This trial is sponsored by Kallyope, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.